Multicenter study of the performance of NTM Elite agar for the detection of nontuberculous mycobacteria from patients with cystic fibrosis

被引:1
作者
Andre, Emmanuel [1 ,2 ]
Lorent, Natalie [3 ]
Beuselinck, Kurt [1 ]
Deiwick, Susanne [4 ]
Dupont, Lieven [3 ]
Gafsi, Johanne [5 ]
Laenen, Lies [1 ,2 ]
Raymaekers, Lise [1 ]
Van Bleyenbergh, Pascal [3 ]
Perry, John D. [6 ]
Kahl, Barbara C. [4 ]
机构
[1] UZ Leuven Univ Hosp, Lab Med Dept, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Lab Clin Microbiol, Leuven, Belgium
[3] Univ Hosp Leuven, Resp Dis Dept, Leuven, Belgium
[4] Univ Hosp Munster, Inst Med Microbiol, Munster, Germany
[5] BioMerieux Global Clin Affairs, Marcy Letoile, France
[6] Freeman Rd Hosp, Microbiol Dept, Newcastle Upon Tyne, England
来源
MICROBIOLOGY SPECTRUM | 2024年 / 12卷 / 10期
关键词
nontuberculous mycobacteria; cystic fibrosis; mycobacterial culture; RAPIDLY-GROWING MYCOBACTERIA; PULMONARY-DISEASE; PREVALENCE;
D O I
10.1128/spectrum.02736-23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The performance of a novel selective agar was evaluated against the performance of conventional mycobacterial cultures, i.e., a combination of the mycobacterial growth indicator tube (MGIT) with L & ouml;wenstein-Jensen (LJ), for the detection of nontuberculous mycobacteria (NTM) in sputum samples from people with cystic fibrosis (pwCF). Two hundred eighty-three sputum samples (231 fresh sputum and 52 spiked sputum) from 143 pwCF were collected. They were inoculated without prior decontamination on NTM Elite agar (30 degrees C +/- 2 degrees C for 28 days) and inoculated on both MGIT and LJ (35 degrees C-37 degrees C for 6-8 weeks) after N-acetyl-L-cysteine-2% sodium hydroxide decontamination. NTM were identified by Matrix-Assisted Laser Desorption Ionization/Time of Flight Mass Spectrometry and/or PCR, and whole-genome sequencing. A total of 67 NTM were recovered overall by the combination of all culture media. NTM Elite agar allowed the recovery of 65 NTM (97%), compared to 22 for the conventional MGIT and LJ media combination (32.8%), including 22 NTM for MGIT (32.8%) and 3 NTM with the LJ medium (4.5%). For Mycobacterium abscessus complex, the sensitivity of NTM Elite agar was 95% compared with a sensitivity of 30% for the conventional MGIT and LJ media combination. Overall, 17.3% of cultures on NTM Elite agar were contaminated with other micro-organisms vs 46.3% on MGIT and 77% on LJ. This study shows that the novel selective agar (NTM Elite agar) significantly outperforms the conventional MGIT and LJ media combination in terms of sensitivity, selectivity, and ease of culture, without the requirement of an L3 laboratory.IMPORTANCENontuberculous mycobacteria (NTM) are significant pulmonary pathogens in patients with pre-existing structural lung conditions such as cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease. Mycobacterium avium complex and Mycobacterium abscessus complex (MABSC) are the most frequently isolated organisms. Compared to the recommended culture method for NTM, which combines solid and liquid culture media, NTM Elite agar enables a faster/easier diagnosis and speeds up identification and susceptibility testing as the final reading is at 28 days instead of 6-8 weeks for the conventional mycobacterial cultures. In addition, for the NTM Elite agar, no decontamination stage before inoculation is necessary, unlike the conventional mycobacterial cultures. NTM Elite agar is derived from a formulation of medium adapted to rapidly growing mycobacteria (RGM). The medium enables the growth of RGM while suppressing other flora. It is supported with published clinical data showing the benefits of this medium. Nontuberculous mycobacteria (NTM) are significant pulmonary pathogens in patients with pre-existing structural lung conditions such as cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease. Mycobacterium avium complex and Mycobacterium abscessus complex (MABSC) are the most frequently isolated organisms. Compared to the recommended culture method for NTM, which combines solid and liquid culture media, NTM Elite agar enables a faster/easier diagnosis and speeds up identification and susceptibility testing as the final reading is at 28 days instead of 6-8 weeks for the conventional mycobacterial cultures. In addition, for the NTM Elite agar, no decontamination stage before inoculation is necessary, unlike the conventional mycobacterial cultures. NTM Elite agar is derived from a formulation of medium adapted to rapidly growing mycobacteria (RGM). The medium enables the growth of RGM while suppressing other flora. It is supported with published clinical data showing the benefits of this medium.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Nontuberculous mycobacteria II: Nested-cohort study of impact on cystic fibrosis lung disease
    Olivier, KN
    Weber, DJ
    Lee, JH
    Handler, A
    Tudor, G
    Molina, PL
    Tomashefski, J
    Knowles, MR
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (06) : 835 - 840
  • [32] Nontuberculous mycobacteria infections of peritoneal dialysis patients: A multicenter study
    Bnaya, Alon
    Wiener-Well, Yonit
    Soetendorp, Hila
    Einbinder, Yael
    Paitan, Yossi
    Kunin, Margarita
    Tanasiychuk, Tatiana
    Kushnir, Daniel
    Kruzel-Davila, Etty
    Gershkovitz, Regina
    Rosenberg, Roza
    Bloch, Aharon
    Doviner, Victoria
    Assous, Marc, V
    Peretz, Orly
    Shavit, Linda
    Ben-Chetrit, Eli
    PERITONEAL DIALYSIS INTERNATIONAL, 2021, 41 (03): : 284 - 291
  • [33] Activities of Dual Combinations of Antibiotics Against Multidrug-Resistant Nontuberculous Mycobacteria Recovered from Patients with Cystic Fibrosis
    Schwartz, Matthew
    Fisher, Stefanie
    Story-Roller, Elizabeth
    Lamichhane, Gyanu
    Parrish, Nicole
    MICROBIAL DRUG RESISTANCE, 2018, 24 (08) : 1191 - 1197
  • [34] Detection of Rapidly Growing Mycobacteria in Routine Cultures of Samples from Patients with Cystic Fibrosis
    Esther, Charles R., Jr.
    Hoberman, Steven
    Fine, Jason
    Allen, Sonia
    Culbreath, Karissa
    Rodino, Kyle
    Kerr, Alan
    Gilligan, Peter
    JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (04) : 1421 - 1425
  • [35] Nontuberculous mycobacteria among pulmonary tuberculosis patients: a retrospective Belgian multicenter study
    De Keukeleire, Steven
    Mathys, Vanessa
    Van den Wijngaert, Sigi
    Van De Vyvere, Martine
    Jonckheere, Stijn
    De Beenhouwer, Hans
    De Bel, Annelies
    de Onate, Wouter Arrazola
    Wanlin, Maryse
    Pierard, Denis
    Nulens, Eric
    Saegeman, Veroniek
    ACTA CLINICA BELGICA, 2017, 72 (01) : 45 - 48
  • [36] Evaluation of Various Culture Media for Detection of Rapidly Growing Mycobacteria from Patients with Cystic Fibrosis
    Preece, Clair L.
    Wichelhaus, Thomas A.
    Perry, Audrey
    Jones, Amanda L.
    Cummings, Stephen P.
    Perry, John D.
    Hogardt, Michael
    JOURNAL OF CLINICAL MICROBIOLOGY, 2016, 54 (07) : 1797 - 1803
  • [37] Diagnostic performance of the Anyplex MTB/NTM real-time PCR in detection of Mycobacterium tuberculosis complex and nontuberculous mycobacteria from pulmonary and extrapulmonary specimens
    Sawatpanich, Ajcharaporn
    Petsong, Suthidee
    Tumwasorn, Somying
    Rotcheewaphan, Suwatchareeporn
    HELIYON, 2022, 8 (12)
  • [38] Improved Decontamination Method for Recovering Mycobacteria from Patients with Cystic Fibrosis
    F.-C. Bange
    E. Böttger
    European Journal of Clinical Microbiology and Infectious Diseases , 2002, 21 : 546 - 548
  • [39] Impacts of Nontuberculous Mycobacteria Isolates in Non-cystic Fibrosis Bronchiectasis: A 16-Year Cohort Study in Taiwan
    Lin, Chun-Yu
    Huang, Hung-Yu
    Hsieh, Meng-Heng
    Fang, Yueh-Fu
    Lo, Yu-Lun
    Lin, Shu-Min
    Huang, Yu-Tung
    Yeh, Chih-Hsin
    Wang, Chun-Hua
    Lin, Horng-Chyuan
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [40] Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the US and Canada
    Morgan, WJ
    Butler, SM
    Johnson, CA
    Colin, AA
    FitzSimmons, SC
    Geller, DE
    Konstan, MW
    Light, MJ
    Rabin, HR
    Regelmann, WE
    Schidlow, DV
    Stokes, DC
    Wohl, MEB
    Kaplowitz, H
    Wyatt, MM
    Stryker, S
    PEDIATRIC PULMONOLOGY, 1999, 28 (04) : 231 - 241